Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy
Clinical & Experimental Allergy · 2024
DOI: 10.1111/cea.14432 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical & Experimental Allergy, 2024. Verfasst von Sviatlana Starchenka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Therapeutics (UK) Plc, Worthing, UK. Hauptthemen laut MEDLINE: Allergens, Transcriptome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergy Therapeutics.
Abstract (Originalsprache)
Introduction
Allergen‐specific immunotherapy (AIT) is the only disease‐modifying treatment in allergic airway diseases. Underlying immunological mechanisms and candidate biomarkers, which may be translated into predictive/surrogate measures of clinical efficacy, remain an active area of research. The aim of this study was to evaluate Pollinex Quattro (PQ) Grass AIT induced immunomodulatory mechanisms, based on transcriptome profiling of peripheral blood mononuclear cells.
Methods
119 subjects with grass pollen induced seasonal allergic rhinitis (SAR) were randomized in a 2:2:1:1 ratio to receive a cumulative dose of PQ Grass as a conventional or extended pre‐seasonal regimen, placebo, or placebo with MicroCrystalline Tyrosine. Gene expression analysis was an exploratory endpoint evaluated in a subgroup of 30 subjects randomly selected from the four treatment arms. Samples were collected at three time points: screening (baseline), before the start of the grass pollen season and at the end of the season. This study was funded by the manufacturer of PQ.
Results
Transcriptome analysis demonstrated that the most significant changes in gene expression, for both treatment regimens, were at the end of the grass pollen season, with the main Th1 candidate molecules (IL‐12A, IFNγ) upregulated and Th2 signature cytokines downregulated (IL‐4, IL‐13, IL‐9) ( p < .05). Canonical pathways analysis demonstrated Th1, Th2, Th17 and IL‐17 as the most significantly enriched pathways based on absolute value of activation z ‐score (I z I score ≥ 2, p < .05). Upstream regulator analysis showed pronounced inhibition of pro‐inflammatory allergic molecules IgE, IL‐17A, IL‐17F, IL‐25 (IL‐17E) (I z I score ≥ 2, FDR < 0.05) and activation of pro‐tolerogenic molecules IL‐12A, IL‐27, IL‐35 (EBI3) at the end of the grass pollen season.
Conclusion
Peripheral blood mononuclear cells transcriptome profile showed an inhibition of Th2, Th17 pro‐inflammatory allergic responses and immune deviation towards Th1 responses. PQ Grass extended regimen exhibited a superior mechanistic efficacy profile in comparison with PQ conventional regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Therapeutics (UK) Plc, Worthing, UK.
- Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.
- Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, UK.
- Bencard Allergie, Munich, Germany.
ORCID-Profile: Sviatlana Starchenka, Kemi Oluwayi, Matthew Heath, Oliver Armfield, Mohamed Shamji, Janice Layhadi, Katarzyna Lis, Lisa Cadavez, Olesya Rusyn, Murray Skinner, Pieter-Jan De Kam
Förderung
- Allergy Therapeutics
Zitieren
APA
Starchenka, S., Oluwayi, K., Heath, M., Armfield, O., Shamji, M., Layhadi, J., Lis, K., Cadavez, L., Rusyn, O., Skinner, M., & De Kam, P. J. (2024). Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14432
Vancouver
Starchenka S, Oluwayi K, Heath M, Armfield O, Shamji M, Layhadi J, et al. Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy. Clinical & Experimental Allergy. 2024. doi:10.1111/cea.14432
BibTeX
@article{Starchenka2024,
author = {Starchenka, Sviatlana and Oluwayi, Kemi and Heath, Matthew and Armfield, Oliver and Shamji, Mohamed and Layhadi, Janice and Lis, Katarzyna and Cadavez, Lisa and Rusyn, Olesya and Skinner, Murray and De Kam, Pieter-Jan},
title = {Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy},
journal = {Clinical & Experimental Allergy},
year = {2024},
doi = {10.1111/cea.14432}
}
EUVIMED